Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.3390/PHARMACEUTICS17030335 | ||||
| Año | 2025 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background/Objectives: This study explores the bioactive potential of Bovistella utriformis biomass and its polysaccharides (PsBu) through comprehensive biochemical and bioactivity analyses, focusing on their antioxidant, cytotoxic, and antihyperglycemic properties. Methods: Elemental analysis determined the biomass's chemical composition. Antioxidant activity was assessed using ABTS and DPPH assays. Monosaccharide composition was analyzed via gas chromatography-mass spectrometry (GC-MS). In vitro cytotoxicity assays were conducted on cancer and normal cell lines to determine IC50 values and selectivity indices (SI). Zebrafish embryo toxicity was evaluated for teratogenic effects, and an in vivo antihyperglycemic study was performed in diabetic rat models. Results: The biomass exhibited high carbon content (around 41%) and nitrogen levels, with a balanced C/N ratio nearing 5. Protein content exceeded 50%, alongside significant carbohydrate, fiber, and ash levels. Antioxidant assays revealed inhibition rates of approximately 89% (ABTS) and 64% (DPPH). GC-MS analysis identified glucose as the predominant sugar (>80%), followed by galactose and mannose. Additionally, HPLC detected a photoprotective compound, potentially a mycosporin-like amino acid. Cytotoxicity assays demonstrated PsBu's selective activity against colon, lung, and melanoma cancer cell lines (IC50: 100-500 mu g<middle dot>mL(-1)), while effects on normal cell lines were lower (IC50 > 1300 mu g<middle dot>mL(-1) for HaCaT, >2500 mu g<middle dot>mL(-1) for HGF-1), with SI values approaching 27, supporting PsBu's potential as a targeted anticancer agent. Zebrafish embryo assays yielded LC50 values ranging from 1.4 to 1.8 mg<middle dot>mL(-1). In vivo, PsBu reduced fasting blood glucose levels in hyperglycemic rats (approximately 210 mg<middle dot>dL(-1) vs. 230 mg<middle dot>dL(-1) in controls) and preserved pancreatic beta-cell integrity (around 80% vs. 65% in controls). Conclusions: These findings suggest that B. utriformis biomass and PsBu exhibit strong antioxidant activity, selective cytotoxicity against cancer cells, and antihyperglycemic potential, making them promising candidates for further biomedical applications.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Maaloul, Aya | - |
Univ Malaga - España
Universidad de Málaga - España |
| 2 | Manriquez, Claudia Perez | - |
Universidad de Concepción - Chile
|
| 3 | Decara, Juan | - |
Hosp Reg Univ Malaga - España
Hospital Regional Universitario Carlos Haya - España |
| 4 | Mari-Beffa, Manuel | - |
Univ Malaga - España
Biomed Res Inst Malaga - España Platform Nanomed IBIMA BIONAND Platform - España Universidad de Málaga - España Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - España |
| 5 | alvarez-Torres, Daniel | - |
Univ Malaga - España
Universidad de Málaga - España |
| 6 | Redoli, Sofia Latorre | - |
Univ Malaga - España
Universidad de Málaga - España |
| 7 | Martinez-Albardonedo, Borja | - |
Universidad de Magallanes - Chile
|
| 8 | Araya-Rojas, Marisel | - |
Universidad de Magallanes - Chile
|
| 9 | FAJARDO-MORALES, VICTOR MANUEL | Hombre |
Universidad de Magallanes - Chile
|
| 10 | Diaz, Roberto T. Abdala | - |
Univ Malaga - España
Universidad de Málaga - España |
| Fuente |
|---|
| FEDER |
| gobierno de España |
| Federación Española de Enfermedades Raras |
| Instituto de Salud Carlos III |
| Andalusian Government |
| ISCIII |
| European Social Fund Plus |
| European Social Fund, "Investing in your future", Gobierno de Espana |
| National System of Health |
| NextGenerationEU and Andalusian Government |
| “Investing in your future” |
| Agradecimiento |
|---|
| This study was funded by the UMA18-FEDERJA-274 grant (Andalusian Government), PCM_00035 (NextGenerationEU and Andalusian Government) and group BIO 217 funds (Andalusian Government and FEDER). Funders had no role in the design or realization of this work. Juan Decara holds a "Miguel Servet" research contract from the National System of Health (CP21/00021), ISCIII cofunded by European Social Fund, "Investing in your future", Gobierno de Espana. |
| This study was funded by the UMA18-FEDERJA-274 grant (Andalusian Government), PCM_00035 (NextGenerationEU and Andalusian Government) and group BIO 217 funds (Andalusian Government and FEDER). Funders had no role in the design or realization of this work. Juan Decara holds a \u201CMiguel Servet\u201D research contract from the National System of Health (CP21/00021), ISCIII cofunded by European Social Fund, \u201CInvesting in your future\u201D, Gobierno de Espa\u00F1a. |